poisar

Stocks · News reference

European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application

Vandana Singh

Valneva (VALN) stock surges after EMA validates MAA for Lyme disease vaccine candidate developed with Pfizer (PFE). Phase 3 trial showed efficacy and no safety concerns, pending regulatory approval.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

PFEVALN
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID?

    Moderna reported positive Phase III results for its personalized mRNA cancer therapy (intismeran autogene) developed with Merck, showing significant improvements in recurrence-free and distant metastasis-free survival in melanoma patients. The breakthrough validates Moderna's mRNA platform beyond vaccines and opens opportunities across multiple tumor types, while the company simultaneously expands its respiratory vaccine portfolio with RSV, flu, and combination vaccines to reduce COVID-19 dependence.

    MRNAMRKPFENVAX
  2. Researchandmarkets.Com

    Immunotherapy Drugs Market 2026: Precision Medicine, Next-Generation Biologics and Expanding Cancer Indications Fuel Growth Opportunities

    The global immunotherapy drugs market is experiencing significant growth driven by advances in biotechnology, rising demand for targeted treatments, and expanding therapeutic applications across cancer, autoimmune, and inflammatory diseases. Key growth factors include increasing disease burden, robust drug pipelines, personalized medicine adoption, and combination therapy development. The Americas and Europe remain dominant markets, while Asia-Pacific is emerging as a high-growth region. Major pharmaceutical and biotech companies are increasing R&D investments and collaboration to accelerate innovation.

    RHHBYMRKLLYPFENVS
  3. Na

    AZN's Etcamah Fails Late-Stage Study for First-line Breast Cancer

    AstraZeneca announced that its phase III SERENA-4 study evaluating Etcamah combined with Pfizer's Ibrance failed to meet its primary endpoint of progression-free survival as first-line treatment for ER-positive, HER2-negative advanced breast cancer, though numerical improvement was observed. The failure does not affect Etcamah's recent FDA approval for a switch strategy in patients with ESR1 resistance mutations.

    AZNPFENVSLLY
  5. Eric Volkman

    Why Pfizer Stock Was so Healthy in August

    Pfizer stock surged nearly 14% in August following better-than-expected Q2 earnings (revenue $15B vs. $14.4B expected, EPS $0.77 vs. $0.68 expected) and raised full-year revenue guidance. The company also achieved regulatory victories with EMA validation for a Lyme disease treatment and FDA approval for an updated COVID vaccine. Despite investor impatience over the lack of new blockbuster products, the analyst views Pfizer as undervalued with a promising pipeline from recent acquisitions.

    PFEBNTXVALN